N-[1-[(6aR,8R,9R,9aS)-9-azido-9-methyl-2,2,4,4-tetra(propan-2-yl)-6,6a,8,9a-tetrahydrofuro[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]-2-oxopyrimidin-4-yl]acetamide | 1403249-53-5

分子结构分类

有机化合物 - 有机氧化合物

中文名称

——

中文别名

——

英文名称

N-[1-[(6aR,8R,9R,9aS)-9-azido-9-methyl-2,2,4,4-tetra(propan-2-yl)-6,6a,8,9a-tetrahydrofuro[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]-2-oxopyrimidin-4-yl]acetamide

英文别名

——

N-[1-[(6aR,8R,9R,9aS)-9-azido-9-methyl-2,2,4,4-tetra(propan-2-yl)-6,6a,8,9a-tetrahydrofuro[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]-2-oxopyrimidin-4-yl]acetamide化学式

CAS

1403249-53-5

化学式

C₂₄H₄₂N₆O₆Si₂

mdl

——

分子量

566.805

InChiKey

TVJJGFQBUYCVJG-VDEHWKIFSA-N

BEILSTEIN

——

EINECS

——

计算性质

辛醇/水分配系数(LogP)：

5.12
重原子数：

38
可旋转键数：

7
环数：

3.0
sp3杂化的碳原子比例：

0.79
拓扑面积：

113
氢给体数：

1
氢受体数：

8

上下游信息

上游原料

中文名称	英文名称	CAS号	化学式	分子量
N-乙酰基-3',5'-O-[1,1,3,3-四(异丙基)-1,3-二硅氧烷二基]胞苷	N4-acetyl-3',5'-O-(tetraisopropyldisiloxane-1,3-diyl)cytidine	85335-73-5	C₂₃H₄₁N₃O₇Si₂	527.765
——	N⁴-acetyl-1-<3,5-O-(tetraisopropyldisiloxane-1,3-diyl)-β-D-erythro-pentofuran-2-ulosyl>cytosine	140859-16-1	C₂₃H₃₉N₃O₇Si₂	525.75
——	N-[1-[(6aR,8R,9aS)-9-methylidene-2,2,4,4-tetra(propan-2-yl)-6a,9a-dihydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]-2-oxopyrimidin-4-yl]acetamide	170112-37-5	C₂₄H₄₁N₃O₆Si₂	523.777
(+)-3’,5’-O-(1,1,3,3-四异丙基-1,3-二硅氧烷)胞苷	3',5'-O-[(1,1,3,3-tetraisopropyl)-1,3-disiloxanediyl]cytidine	69304-42-3	C₂₁H₃₉N₃O₆Si₂	485.728
胞苷	CYTIDINE	65-46-3	C₉H₁₃N₃O₅	243.219

下游产品

中文名称	英文名称	CAS号	化学式	分子量
——	1-[(6aR,8R,9R,9aS)-9-azido-9-methyl-2,2,4,4-tetra(propan-2-yl)-6,6a,8,9a-tetrahydrofuro[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]-4-aminopyrimidin-2-one	1403249-66-0	C₂₂H₄₀N₆O₅Si₂	524.768
——	1-[(6aR,8R,9R,9aS)-9-amino-9-methyl-2,2,4,4-tetra(propan-2-yl)-6,6a,8,9a-tetrahydrofuro[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]-4-aminopyrimidin-2-one	1403249-67-1	C₂₂H₄₂N₄O₅Si₂	498.77
——	N-[(6aR,8R,9R,9aS)-8-(4-amino-2-oxopyrimidin-1-yl)-9-methyl-2,2,4,4-tetra(propan-2-yl)-6,6a,8,9a-tetrahydrofuro[3,2-f][1,3,5,2,4]trioxadisilocin-9-yl]acetamide	1403249-68-2	C₂₄H₄₄N₄O₆Si₂	540.808
——	N-[1-[(2R,3R,4S,5R)-3-azido-4-hydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]-2-oxopyrimidin-4-yl]acetamide	1403567-97-4	C₁₂H₁₆N₆O₅	324.296
——	propan-2-yl (2S)-2-[[[(2R,3S,4R,5R)-4-azido-3-hydroxy-4-methyl-5-[4-(2-methylpropanoylamino)-2-oxopyrimidin-1-yl]oxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate	1605283-90-6	C₂₆H₃₆N₇O₉P	621.587
——	N-[1-[(6aR,8R,9R,9aS)-9-methyl-2,2,4,4-tetra(propan-2-yl)-9-(triazol-1-yl)-6,6a,8,9a-tetrahydrofuro[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]-2-oxopyrimidin-4-yl]acetamide	1403249-64-8	C₂₆H₄₄N₆O₆Si₂	592.843
——	[(2R,3S,4R,5R)-4-azido-4-methyl-5-[4-(2-methylpropanoylamino)-2-oxopyrimidin-1-yl]-2-[[[[(2S)-1-oxo-1-propan-2-yloxypropan-2-yl]amino]-phenoxyphosphoryl]oxymethyl]oxolan-3-yl] 2-methylpropanoate	1605283-89-3	C₃₀H₄₂N₇O₁₀P	691.678
——	4-amino-1-[(2R,3R,4S,5R)-3-azido-4-hydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]pyrimidin-2-one	1403249-54-6	C₁₀H₁₄N₆O₄	282.259
——	propan-2-yl (2S)-2-[[[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-azido-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate	1403574-71-9	C₂₂H₃₀N₇O₈P	551.496
——	methyl (2S)-2-[[[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-azido-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate	1403568-00-2	C₂₀H₂₆N₇O₈P	523.442
——	1-[(4aR,6R,7R,7aS)-7-azido-7-methyl-2-oxo-2-propan-2-yloxy-4,4a,6,7a-tetrahydrofuro[3,2-d][1,3,2]dioxaphosphinin-6-yl]-4-aminopyrimidin-2-one	1403250-40-7	C₁₃H₁₉N₆O₆P	386.304
——	[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-azido-3-hydroxy-4-methyloxolan-2-yl]methyl (2-chlorophenyl) propan-2-yl phosphate	1403250-39-4	C₁₉H₂₄ClN₆O₇P	514.862
——	[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-azido-4-methyl-2-[[[[(2S)-1-oxo-1-propan-2-yloxypropan-2-yl]amino]-phenoxyphosphoryl]oxymethyl]oxolan-3-yl] 2-methylpropanoate	1605283-86-0	C₂₆H₃₆N₇O₉P	621.587
——	propan-2-yl (2S)-2-[[[(2R,3S,4R,5R)-4-amino-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate	1403250-92-9	C₂₂H₃₂N₅O₈P	525.499
——	1-[(4aR,6R,7R,7aS)-7-amino-7-methyl-2-oxo-2-propan-2-yloxy-4,4a,6,7a-tetrahydrofuro[3,2-d][1,3,2]dioxaphosphinin-6-yl]-4-aminopyrimidin-2-one	1403250-41-8	C₁₃H₂₁N₄O₆P	360.307
——	N-[(2R,3R,4S,5R)-2-(4-amino-2-oxopyrimidin-1-yl)-4-hydroxy-5-(hydroxymethyl)-3-methyloxolan-3-yl]acetamide	1403249-69-3	C₁₂H₁₈N₄O₅	298.299
——	methyl (2S)-2-[[[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxy-4-methyl-4-(triazol-1-yl)oxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate	1403249-80-8	C₂₂H₂₈N₇O₈P	549.48
——	4-amino-1-[(2R,3R,4S,5R)-3-amino-4-hydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]pyrimidin-2-one	1403249-61-5	C₁₀H₁₆N₄O₄	256.261
——	4-amino-1-[(2R,3R,4S,5R)-4-hydroxy-5-(hydroxymethyl)-3-methyl-3-(triazol-1-yl)oxolan-2-yl]pyrimidin-2-one	1403249-65-9	C₁₂H₁₆N₆O₄	308.297

反应信息

作为反应物：

描述：

N-[1-[(6aR,8R,9R,9aS)-9-azido-9-methyl-2,2,4,4-tetra(propan-2-yl)-6,6a,8,9a-tetrahydrofuro[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]-2-oxopyrimidin-4-yl]acetamide 在 N-甲基咪唑、 potassium tert-butylate 、四丁基氟化铵作用下，以四氢呋喃为溶剂，反应 6.5h，生成 1-[(4aR,6R,7R,7aS)-7-azido-2-[2-[2-(tert-butyldisulfanyl)phenyl]ethoxy]-7-methyl-2-oxo-4,4a,6,7a-tetrahydrofuro[3,2-d][1,3,2]dioxaphosphinin-6-yl]-4-aminopyrimidin-2-one

参考文献：

名称：

[EN] MONONUCLEOTIDES HAVING A BIOREVERSIBLE DISULFIDE GROUP
[FR] MONONUCLÉOTIDES COMPORTANT UN GROUPE DISULFURE BIORÉVERSIBLE

摘要：

公开号：

WO2016094677A3
作为产物：

描述：

胞苷在 Carreira’s cobalt catalyst 吡啶、对甲苯磺酰叠氮、双(三甲基硅烷基)氨基钾、戴斯-马丁氧化剂作用下，以四氢呋喃、乙醇、二氯甲烷为溶剂，反应 38.19h，生成 N-[1-[(6aR,8R,9R,9aS)-9-azido-9-methyl-2,2,4,4-tetra(propan-2-yl)-6,6a,8,9a-tetrahydrofuro[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]-2-oxopyrimidin-4-yl]acetamide

参考文献：

名称：

[EN] 2'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES
[FR] DÉRIVÉS DE NUCLÉOSIDE 2'-SUBSTITUÉS ET PROCÉDÉS D'UTILISATION DE CEUX-CI POUR LE TRAITEMENT DE MALADIES VIRALES

摘要：

本发明涉及式(I)的2'-取代核苷衍生物及其药学上可接受的盐，其中A、B、X、R1、R2和R3如本文所定义。本发明还涉及包含至少一种2'-取代核苷衍生物的组合物，以及使用这些2'-取代核苷衍生物治疗或预防患者HCV感染的方法。

公开号：

WO2012142085A1

点击查看最新优质反应信息

文献信息

[EN] 2'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES<br/>[FR] DÉRIVÉS DE NUCLÉOSIDE 2'-SUBSTITUÉS ET PROCÉDÉS D'UTILISATION DE CEUX-CI POUR LE TRAITEMENT DE MALADIES VIRALES

申请人：MERCK SHARP & DOHME

公开号：WO2012142085A1

公开（公告）日：2012-10-18

The present invention relates to 2'-Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, X, R1, R2 and R3 are as defined herein. The present invention also relates to compositions comprising at least one 2'-Substituted Nucleoside Derivative, and methods of using the 2'-Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.

本发明涉及式(I)的2'-取代核苷衍生物及其药学上可接受的盐，其中A、B、X、R1、R2和R3如本文所定义。本发明还涉及包含至少一种2'-取代核苷衍生物的组合物，以及使用这些2'-取代核苷衍生物治疗或预防患者HCV感染的方法。
2'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

申请人：Girijavallabhan Vinay

公开号：US20140206640A1

公开（公告）日：2014-07-24

The present invention relates to 2′-Azido Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, R 1 , R 2 and R 3 are as defined herein. The present invention also relates to compositions comprising at least one 2′-Azido Substituted Nucleoside Derivative, and methods of using the 2′-Azido Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.

本发明涉及式(I)的2'-叠氮基取代核苷衍生物及其药学上可接受的盐，其中B、X、R1、R2和R3如本文所定义。本发明还涉及包含至少一种2'-叠氮基取代核苷衍生物的组合物，以及使用这些2'-叠氮基取代核苷衍生物治疗或预防患者HCV感染的方法。
[EN] 2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES<br/>[FR] DÉRIVÉS DE NUCLÉOSIDES 2'-MÉTHYLE SUBSTITUÉS ET LEURS PROCÉDÉS D'UTILISATION DANS LE TRAITEMENT DE MALADIES VIRALES

申请人：MERCK SHARP & DOHME

公开号：WO2014062596A1

公开（公告）日：2014-04-24

The present invention relates to 2'-Methyl Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R, R1, R2 and R3, are as defined herein. The present invention also relates to compositions comprising at least one 2'-Methyl Substituted Nucleoside Derivative, and methods of using the 2'-Methyl Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.

本发明涉及式(I)的2'-甲基取代核苷衍生物及其药学上可接受的盐，其中R、R1、R2和R3如本文所定义。本发明还涉及包含至少一种2'-甲基取代核苷衍生物的组合物，以及使用这些2'-甲基取代核苷衍生物治疗或预防患者HCV感染的方法。
[EN] MONONUCLEOTIDES HAVING A BIOREVERSIBLE DISULFIDE GROUP<br/>[FR] MONONUCLÉOTIDES COMPORTANT UN GROUPE DISULFURE BIORÉVERSIBLE

申请人：SOLSTICE BIOLOG LTD

公开号：WO2016094677A3

公开（公告）日：2016-07-28

N-[1-[(6aR,8R,9R,9aS)-9-azido-9-methyl-2,2,4,4-tetra(propan-2-yl)-6,6a,8,9a-tetrahydrofuro[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]-2-oxopyrimidin-4-yl]acetamide | 1403249-53-5

分子结构分类

计算性质

上下游信息

反应信息

文献信息

同类化合物

相关结构分类

热门分子